Top-News
Biotechnologie USA

Palatin Technologies Inc Aktie

Aktie
WKN:  A3DTUW ISIN:  US6960775020 US-Symbol:  PTN
0,1846 €
+0,0026 €
+1,43%
13:11:16 Uhr
Depot/Watchlist
Aktienanzahl *
19,37 Mio.
Marktkapitalisierung *
3,89 Mio. €
Streubesitz
83,19%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 03.09.2024

Palatin Technologies Inc News

17.04.25 - PR Newswire
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide PR Newswire
14.04.25 - PR Newswire
Palatin Appeals NYSE American Notice of Delisting
Palatin Appeals NYSE American Notice of Delisting PR Newswire
10.04.25 - PR Newswire
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal PR Newswire
10.04.25 - PR Newswire
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting PR Newswire
31.03.25 - PR Newswire
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Palatin Announces MC4R Agonist Bremelanotide Co-​Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study PR Newswire
28.03.25 - PR Newswire
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 PR Newswire
25.03.25 - PR Newswire
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency PR Newswire
13.02.25 - PR Newswire
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire
10.02.25 - PR Newswire
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025 PR Newswire
07.02.25 - PR Newswire
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement PR Newswire
06.02.25 - PR Newswire
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide PR Newswire
28.01.25 - PR Newswire
Palatin Provides Update on Anticipated 2025 Corporate Milestones
Palatin Provides Update on Anticipated 2025 Corporate Milestones PR Newswire
19.12.24 - PR Newswire
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy PR Newswire
16.12.24 - PR Newswire
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds PR Newswire
25.11.24 - PR Newswire
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis PR Newswire
14.11.24 - PR Newswire
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results PR Newswire
08.11.24 - PR Newswire
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 PR Newswire
04.11.24 - PR Newswire
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 PR Newswire
31.10.24 - PR Newswire
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-​Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity PR Newswire
24.10.24 - PR Newswire
Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium PR Newswire

Newssuche

Videos

newspaper
22.04.25 +5,19%
Technical Trading: US-​Anleihen Long bis September
10yr T-Notes Long Typ: Turbo Open End WKN: NG8ZZF Hebel: 14,89 Laufzeit: OpenEnd Einstieg: Market ... Mehr »